Clinical Trial Update: CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting completion of a study evaluating CD19-targeted CAR T cells in relapsed or refractory CD19-positive B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19 CAR T cells

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Lymphomas Non-Hodgkin's B-Cell, Relapse | Phase 1 | Status: COMPLETED